SCHEMBL2413263

SCHEMBL2413263

Cc1nc2c(C)cccc2nc1C(=O)CC#N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 4/20 0.36
MEN1 O00255 3/20 0.36
NPSR1 Q6W5P4 3/20 0.36
RXFP1 Q9HBX9 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALDH1A1 P00352 4/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
KCNH2 Q12809 1/20 0.35
KDM4E B2RXH2 2/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
AGPAT2 O15120 1/20 0.34
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2407871 0.94 MAPT (0.37) MAPTMAPK1RAB9AKMT2AMEN1
SCHEMBL2412550 0.84 MAPT (0.43) MAPTMAPK1KMT2AMEN1TDP1
SCHEMBL2407906 0.78 KDM4E (0.35) MAPTRAB9AKMT2AMEN1TDP1
SCHEMBL2413046 0.74 CYP1A2 (0.49) MAPTMAPK1RAB9AKMT2AMEN1
SCHEMBL2408384 0.74 MAPT (0.46) MAPTRAB9AKMT2AMEN1TDP1
SCHEMBL2409584 0.74 MAPT (0.46) MAPTRAB9AKMT2AMEN1TDP1
SCHEMBL2407795 0.74 TDP1 (0.42) MAPTMAPK1RAB9AKMT2AMEN1
SCHEMBL2407523 0.74 KDM5B (0.34) MAPTRAB9AKMT2AMEN1NPSR1
SCHEMBL2410689 0.73 KCNH2 (0.35) MAPTKMT2AMEN1ALDH1A1KCNH2
SCHEMBL2407674 0.71 TSHR (0.41) MAPTKMT2ATDP1KCNH2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2539342-B1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2015-04-15 EP disclosed
US-8969376-B2 Pyrazolopyrimidine compounds and their use as PDE10 inhibitors MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-03-03 US disclosed
EP-2539342-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS Mitsubishi Tanabe Pharma Corporation (JP) 2013-01-02 EP disclosed
US-20120309754-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-12-06 US disclosed
WO-2011105628-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309754-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PDE3B, PDE3A, PDE5A MAPT 4404/4885MAPK1 286/4885RAB9A 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.